GlassScriptPhysician profile
Zi Zhang
NPI 1487005351
$950.29
in general payments reported to CMS, 2019-2025
14 companies · $917 in 2025
The $917 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $33.57 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Education: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.91 |
| Education | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $160.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.85 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $122.29 | 2025 | |
| Amgen INC. | $115.36 | 2025 | Uplizna, Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $91.53 | 2025 | Filspari |
| Aurinia Pharma U.S., INC. | $58.89 | 2025 | Lupkynis |
| Lilly USA, LLC | $53.73 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2025 | Jynarque, Voyxact |
| Cormedix INC. | $33.57 | 2024 | Defencath |
| Novartis Pharmaceuticals Corporation | $33.01 | 2025 | |
| Calliditas Therapeutics US INC. | $32.74 | 2025 | Tarpeyo |
| Daiichi Sankyo INC. | $28.57 | 2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $19.61 | 2025 | Lokelma |
| Vifor Pharma, INC. | $16.47 | 2025 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zi Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.